Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren Fiskus

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Blood|April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
American Journal of Hematology|October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsNicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Leukemia|December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AMLDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Blood|February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitorsDyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Pathology|March 18, 2023
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphomaSiba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Blood|April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
American Journal of Hematology|October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsNicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Leukemia|December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AMLDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Blood|February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitorsDyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Pathology|March 18, 2023
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphomaSiba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, et al.
Pageof 10